Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-72.

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.

WHO CVD Atlas WHO Stroke Atlas The Burden of CVD in Asia: Stroke Deaths by Country,

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:

Effect of High-dose Angiotensin II Receptor Blocker (ARB) Monotherapy versus ARB plus Calcium Channel Blocker Combination on Cardiovascular Events in Japanese.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Randomized, double-blind, multicenter, controlled trial.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.

ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,

Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.

Philip J. Barter, et al. Circulation 2011;124:

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Update on Valsartan Špinar J.. System renin-angiotensin-aldosteron angiotensinogen angiotensin I angiotensin II aldosteron ANP,BNP thirst resorp. Na +

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

A Diabetes Outcome Progression Trial

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.

Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.

Diabetes and Cause-Specific Mortality in a Prospective Cohort of One Million U.S. Adults Featured Article: Peter T. Campbell, Ph.D., Christina C. Newton,

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Predictive value of CRP vs LDL-C (i) Ridker PM, et al. N Engl J Med 2002;347: Quintile of CRP (mg/L)

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Urinary Sodium and Potassium Excretion and Risk of.

Date of download: 7/1/2016 From: Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2015;162(4):

Date of download: 7/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Fibroblast Growth Factor 23 and Risks of Mortality.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Copyright © 2015 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved.

Career choice for Chinese medical graduate: Safety Physician

Copyright © 2014 American Medical Association. All rights reserved.

TNT: Baseline and final LDL cholesterol levels

Prevalence of statin and beta-blocker use by clinical presentation

Fung TT, et al. Circulation 2009;119:

(p for noninferiority < 0.001)

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Enrollment and Outcomes

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Berger JS, et al. JAMA 2009;301:

Distribution of Cardiovascular Risk Factors by Baseline CRP Concentration M. Cushman et al. Circulation. 2005;112:25-31.

Baseline Characteristics According to Sex

Baseline Characteristics of the Study Participants

Women’s Health Study: Baseline Characteristics Part 1

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Baseline Characteristics of the Patients – Part I

Baseline characteristics of older women (NHS I), younger women (NHS II), and men (HPFS) with a history of hypertension according to thiazide use Eric N.

Baseline Characteristics by hs-CRP

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Presentation transcript:

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

Baseline Personal Characteristics Stratified by Sex in Relation to Diabetes Mellitus and a Prior MI - Part I Tina Ken Schramm, et al. Circulation 2008;117:

Baseline Personal Characteristics Stratified by Sex in Relation to Diabetes Mellitus and a Prior MI - Part II Tina Ken Schramm, et al. Circulation 2008;117:

Numbers of Events During the Study Period ( ) for Different End Points Stratified by Sex in Relation to Diabetes Mellitus and a Prior MI Tina Ken Schramm, et al. Circulation 2008;117:

Age- and Multivariable-Adjusted Cox Multivariable Proportional-Hazard Analysis Stratified by Sex Demonstrating Relative Hazards for Different End Points in Relation to Diabetes Mellitus and a Prior MI Tina Ken Schramm, et al. Circulation 2008;117:

Event rates for cardiovascular mortality in men (A) and women (B) stratified by age and sex in relation to diabetes mellitus (DM) and a prior MI Tina Ken Schramm, et al. Circulation 2008;117:

Event rates for the composite end point of MI (nonfatal), stroke (nonfatal), and cardiovascular death in men (A) and women (B) stratified by age in relation to diabetes mellitus (DM) and a prior MI Tina Ken Schramm, et al. Circulation 2008;117:

Secular trends for medical treatment in percentage during follow-up in relation to diabetes mellitus and a prior MI. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker Tina Ken Schramm, et al. Circulation 2008;117:

Age-adjusted Cox multivariable proportional-hazard analysis stratified by sex demonstrating secular trends in relative risks (RR) for different end points in relation to diabetes mellitus and a prior MI, with nondiabetics without a prior MI as the reference Tina Ken Schramm, et al. Circulation 2008;117:

CLINICAL PERSPECTIVE Tina Ken Schramm, et al. Circulation 2008;117: